The rosacea treatment industry is witnessing significant advancements as the need for tacking rosacea burden grows. Companies are constantly introducing new therapies and expanding establishing options to manage symptoms associated with rosacea.
In November 2024, Journey Medical Corporation received U.S. Food and Drug Administration (FDA) approval for Emrosi (Minocycline HCL) for the treatment of rosacea. Emrosi was developed by the company in collaboration with Dr. Reddy’s Laboratories Ltd. Its approval is supported by positive data from the company’s two phase 3 clinical trials for the rosacea treatment.
Emrosi’s FDA approval marks a significant milestone in rosacea treatment landscape. It will help millions of rosacea patients in the United States to reduce their symptoms. This novel drug has the potential to become the best-in-class oral medication to treat rosacea.
In July 2024, Sol-Gel Technologies Ltd., a prominent dermatology company that provides treatments for patients with severe skin conditions, signed six exclusive agreements to commercialize EPSOLAY and TWYNEO in Europe and South Africa. EPSOLAY and TWYNEO are innovative treatments for rosacea and acne. Their expansion into South Africa and Europe through exclusive agreements could improve patient access to advanced dermatological solutions.
Galderma launched EPSOLAY Cream in the United States after receiving FDA approval recently. It is the first microencapsulated benzoyl peroxide (E-BPO) topical treatment to provide relief from bumps and blemishes of rosacea.
These developments reflect the industry’s commitment to move further in rosacea treatment options as well as improving patient outcomes. Approval of new drugs, like that of Journey Medical’s Emrosi, will play a key role in tackling the rosacea burden.
Introduction of novel therapies, regulatory approvals, and strategic collaborations highlight the growing efforts to address the growing prevalence of rosacea. They will play a key role in expanding the target industry’s scope.
According to Coherent Market Insights (CMI), the global rosacea treatment industry size is set to reach US$ 2.96 billion by 2030, expanding at a CAGR of 6.5%. This growth will likely be driven by continuous innovation in treatment options, such as the FDA approval of Emrosi and the expansion of EPSOLAY and TWYNEO into new regions.
Development of new therapies with enhanced efficacy and accessibility is expected to improve treatment availability. With companies continuing to invest in research and development, the target industry is set to witness further advancements in targeted therapies.
Other factors expected to bolster the industry’s growth include rising incidence of rosacea and favourable government support. Rising health awareness and improvement in rosacea diagnostics will also benefit the industry during the assessment period.
